A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVE dataset
| Field | Value | Language |
| dc.contributor.author | Sjoquist, Katrin | |
| dc.date.accessioned | 2024-07-16T05:45:36Z | |
| dc.date.available | 2024-07-16T05:45:36Z | |
| dc.date.issued | 2024-07-16 | |
| dc.identifier.uri | https://hdl.handle.net/2123/32798 | |
| dc.description.abstract | This dataset includes 24 female participants (38 - 86 years old) receiving intraperitoneal bevacizumab recruited into the REZOLVE study from six hospitals in New South Wales, Queensland and Victoria, Australia. Baseline data includes demographics, ECOG performance status, prior systemic treatment, doses of the intervention administered, clinical chemistry, quality of life, adverse events and overall survival. Follow-up data was collected within three months after the first intraperitoneal administration of bevacizumab and includes adverse events and quality of life. The file type is .XLS. | en |
| dc.rights | Other | en |
| dc.title | A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVE dataset | en |
| dc.type | Dataset | en |
| dc.identifier.doi | 10.25910/edvb-4889 | |
| dc.rights.other | Access can be requested via the Health Data Australia catalogue (https://researchdata.edu.au/health). A copy of the Data Sharing Policy can be found in https://rb.gy/bgrcq. For further information please contact the Health Studies Australian National Data Asset (HeSANDA) SHP-CTC node ([email protected]). | en |
| usyd.faculty | SeS faculties schools::Faculty of Medicine and Health::NHMRC Clinical Trials Centre | en |
| workflow.metadata.only | Yes | en |
Associated file/s
There are no files associated with this item.
Associated collections